© Reuters. AbbVie earnings beat by $0.07, revenue fell short of estimates
Investing.com – AbbVie (NYSE: ABBV) reported fourth quarter EPS of $3.60, $0.07 better than the analyst estimate of $3.53. Revenue for the quarter came in at $15.12B versus the consensus estimate of $15.33B.
Guidance
AbbVie sees FY 2023 EPS of $10.70-$11.10 versus the analyst consensus of $11.65.
AbbVie’s stock price closed at $144.61. It is down -3.70% in the last 3 months and up 1.33% in the last 12 months.
AbbVie saw 1 positive EPS revisions and 12 negative EPS revisions in the last 90 days. See AbbVie’s stock price’s past reactions to earnings here.
According to InvestingPro, AbbVie’s Financial Health score is “great performance“.
Check out AbbVie’s , and AbbVie’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Be the first to comment